医药企业近日陆续披露年报预告，据东方财富Choice数据统计，截至目前，A股医药生物板块有137家 企业预告2025年亏损，其中首亏、增亏的企业数量占比一半以上；而预计去年归属于母公司的净利润亏 损最高的，达到137亿元。 药企亏损的背后，受制于多方面因素，其中产品价格下跌成为高频词。 亏损最高的超百亿 具体看这137家预告亏损的医药生物企业，涵盖了原料药、化学制剂、中药、疫苗、医药流通、体外诊 断、医疗耗材、医疗研发外包、医疗设备等细分领域，从预告归属于母公司的净利润下限指标看，亏损 最大的是智飞生物（300122.SZ），去年业绩首亏，公司预计归属于母公司的净利润亏损最高可达到 137.26亿元；紧接着是珍宝岛（603567.SH），预计去年归属于母公司的净利润亏损最高可达到11.73亿 元；之后是百利天恒（688506.SH），预计去年归属于母公司的净利润亏损最高可达到11亿元。 另外，蓝帆医疗（002382.SZ）、神州细胞（688520.SH）、润达医疗（603108.SH）、广济药业 （000952.SZ）这四家企业预计去年归属于母公司的净利润亏损最高可超过5亿元。 A股医药生物板块企业的亏损，受 ...

大家早上好呀~ 小晚带来 每日新闻速递啦！ ，读深圳晚报 今日天气 | 今天 | 明天 | 周三 | 周四 | 周五 | 周六 | 周日 | | --- | --- | --- | --- | --- | --- | --- | | 2月2日 | 2月3日 | 2月4日 | 2月5日 | 2月6日 | 2月7日 | 2月8日 | | 晴天间多云 | 晴天间少云 | 多云,早晚 | 多云,早晚 | 多云间阴 | 多云间阴 | 晴天间多云 | | | | 有轻雾 | 有轻雾 | 天,有零星 | 天, 有零星 | | | | | | | 小雨 | 小雨 | | | | | | | | ← | | | 东北风 | 东风 | 东风 | 东风 | 东转东北风 | 东北风 | 东北风 | | 3 级 | 2-3 级 | 2-3 级 | 2-3 级 | 2-3 级 | 3 级 | 3 级 | | 35-65 % | 50-80 % | 55-85 % | 65-95 % | 65-95 % | 55-85 % | 50-75 % | | | 23 °C | 24 °C | 25 °C | 26 °C | | | | 22 ° ...

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is currently facing short-term performance pressure due to weak demand and structural oversupply, with many companies experiencing declines or losses in performance [1][7][8] - Despite the challenges, innovation and international expansion are ongoing, providing potential for medium to long-term growth [1][8] - The industry is transitioning from scale expansion to innovation-driven growth, with policy, demand, and technology as the three main driving factors for development [8][24][26] Summary by Sections Domestic and International Vaccine Dynamics - Kanghua Biotech has initiated Phase I clinical trials for its six-valent norovirus vaccine, which theoretically can prevent over 90% of norovirus infections [1] - Wantai Biopharma's bivalent HPV vaccine has successfully passed the WHO PQ periodic review [1] - Zhifei Biological's application for clinical trials of a freeze-dried inactivated vaccine for Japanese encephalitis has been accepted [1] Performance Forecasts - Chengda Bio expects a 59.34%-63.98% decrease in net profit for 2025 compared to the previous year [1] - CanSino anticipates a revenue increase of 22.88%-27.61% for 2025, with a turnaround in net profit [1] - Watson Bio forecasts a revenue of 2.4-2.43 billion yuan for 2025, a decline of approximately 14.9%-13.9% [1] - Other companies like Kangtai Bio and Wantai Bio also expect significant declines in net profit for 2025 [1] Market Performance - The vaccine sector saw a decline of 1.65% last week, with the overall pharmaceutical industry down 3.31% [2][5] - The vaccine sector has experienced a cumulative decline of 10.08% since the beginning of 2025 [5][13] Valuation Metrics - The vaccine sector's PE (ttm) is 92.01X, down 1.88X from the previous week, while the PB (lf) is 1.78X, down 0.04X [6] - The PE is at the 55.99% percentile since 2013, and the PB is at the 1.28% percentile since 2013 [6] Investment Recommendations - The vaccine industry is still under pressure, but companies are actively adjusting their pipeline strategies, focusing on technological innovation and multi-valent products [7][8] - Long-term prospects remain positive due to innovation and international market expansion, with a recommendation to focus on companies with strong R&D capabilities and differentiated product offerings, such as CanSino [8][26]

百余家医药企业发布业绩预告 19家年内实现业绩翻身 1月30日，新京报贝壳财经记者根据Wind数据整理发现，474家医药企业中，255家已发布2025年业绩预告。81家企业释放出积极信号，其中，50家企业出现 业绩预增，6家业绩略增。 | 业绩预告类型 | 数量 | | --- | --- | | 不确定 | 1 | | 略減 | 3 | | 略增 | 6 | | 扭亏 | 24 | | 首亏 | 38 | | 续亏 | 90 | | 续盈 | 1 | | 预减 | 42 | | 预增 | 50 | | 总数 | 255 | 近日，A股医药板块上市公司开始密集披露2025年度业绩预告。据新京报贝壳财经统计，截至1月30日，已有255家相关企业公布了业绩预告数据。 其中超三成企业释放积极信号——50家业绩预增、24家实现扭亏，打赢"翻身仗"，化学制药、医疗器械、医疗服务等领域企业表现突出。 值得注意的是，海外市场成为多家企业增长的共同引擎。以理邦仪器为例，公司在业绩预告中强调"国际市场保持两位数增长"。与此同时，部分企业通过降 本增效、产品结构调整成功实现业绩逆转。 行业内部亦呈现结构性分化，从2025年业绩表 ...

万泰生物首次募集资金总额为3.82亿元，募集资金净额为3.18亿元。万泰生物2020年4月14日发布招 股书显示，募集资金中1.50亿元用于化学发光试剂制造系统自动化技术改造及国际化认证项目，1.50亿 元用于宫颈癌疫苗质量体系提升及国际化项目，1784.81万元用于营销网络中心扩建项目。 中国经济网北京1月30日讯 万泰生物(603392.SH)昨日晚间发布2025年年度业绩预亏公告。经财务部 门初步测算，预计2025年年度实现归属于母公司所有者的净利润为-41,000万元到-33,000万元，与上年 同期相比，将出现亏损。预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润 为-66,000万元到-53,000万元。 2024年，万泰生物实现归属于母公司所有者的净利润10,624万元；归属于母公司所有者的扣除非经 常性损益的净利润-18,644万元。 万泰生物于2020年4月29日在上交所主板上市，公开发行股票4360万股，发行价格为8.75元/股，保 荐机构为国金证券股份有限公司。 (责任编辑：田云绯) 万泰生物首次发行费用为6365.19万元，其中，国金证券获得承销及保荐费用4346.0 ...

影响股市利好与利空消息 宏观新闻 1、国务院办公厅日前印发《加快培育服务消费新增长点工作方案》，其中提到，研究稳妥扩大单方面 免签、过境免签、区域性免签政策适用范围。其中还提到，鼓励地方结合消化存量房地产等政策落实， 支持旅居项目用地和服务设施建设。 2、商务部昨日举行例行新闻发布会。有记者提问称：美国贸易代表日前在达沃斯表示，在可能举行的 中美领导人会晤之前，中美双方有机会开启新一轮经贸谈判。新闻发言人何咏前表示，中方愿与美方共 同维护好、落实好两国元首重要共识，用好中美经贸磋商机制，管控分歧、推进合作，促进中美经贸关 系稳定、健康、可持续发展。 3、中英双方在英国首相斯塔默访华期间达成一系列积极成果，其中，中方将威士忌酒进口关税税率由 10%降至5%。 4、中国人民银行行长潘功胜1月28日会见了来访的高盛集团董事长兼首席执行官苏德巍。双方就全球经 济金融形势、中国宏观经济政策、中美经贸关系等议题进行了交流。 5、外交部发言人郭嘉昆昨日主持例行记者会。记者提问称，据报道，中国已批准进口首批英伟达的 H200人工智能芯片。郭嘉昆表示，具体问题建议向中方主管部门进行询问。 6、美国总统特朗普29日表示，鉴于严寒 ...

Group 1: Company Announcements - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder post-restructuring [1] - Silver Industry's gold and silver product revenues are low, with gold sales contributing 18.67% and silver 4.54% to total revenue in H1 2025 [2] - Tianneng Wind Power has decided to implement long-term production halts for six wholly-owned subsidiaries to optimize resource allocation and focus on core offshore wind power business [3] Group 2: Price and Supply Risks - Tongling Nonferrous Metals reports significant uncertainty in the prices of cathode copper and other main products, with low self-sufficiency in copper concentrate posing supply stability risks [4] - ST Aowei received a notice of termination of listing due to market capitalization falling below 500 million yuan for 20 consecutive trading days [5][6] Group 3: Performance Forecasts - Foton Motor expects a net profit increase of approximately 1551% to around 1.33 billion yuan in 2025, driven by sales growth across various segments [7] - Beimo High-Tech anticipates a net profit of 190 million to 220 million yuan, reflecting a growth of 1076.16% to 1261.87% [8] - Zhongke Sanhuan forecasts a net profit increase of 566.23% to 899.35%, driven by cost control and market expansion [9] - Wancheng Group expects a net profit of 1.23 billion to 1.4 billion yuan, a growth of 222.38% to 266.94% [10] - Wan Yi Technology anticipates a net profit increase of 191.52% to 330.34%, supported by product optimization and cost reduction measures [11] - Nanmo Biology expects a net profit of 24 million to 34 million yuan, a growth of 269.49% to 423.44% [12] - Bai'ao Saitou forecasts a net profit increase of 384.26% to 443.88%, benefiting from overseas market expansion [13] - Hailanxin anticipates a net profit of 40 million to 60 million yuan, a growth of 387.47% to 631.2% [14] - Panzhihua Coal expects a net profit of 318 million to 380 million yuan, a growth of 205.3% to 264.83% [15] - Huaguang New Materials forecasts a net profit increase of 104.67% to 141.88% [16] - Putian Technology expects a net profit of 1.92 million to 2.88 million yuan, a growth of 71.55% to 157.33% [17] - Guoda Special Materials anticipates a net profit increase of 82.61% [18] - Tongkun Co. expects a net profit of 1.95 billion to 2.15 billion yuan, a growth of 62.24% to 78.88% [19] - Yiming Pharmaceutical forecasts a net profit increase of 61.12% to 122.08% [20] - Guosheng Securities expects a net profit of 210 million to 280 million yuan, a growth of 25.44% to 67.25% [21] - Shengyi Technology anticipates a net profit increase of 87% to 98% [22] Group 4: Loss Forecasts - Saifutian expects a loss of 30 million to 45 million yuan, significantly reducing previous losses [23] - Magang Group forecasts a loss of 190 million to 250 million yuan, a substantial reduction in losses [24] - Shennong Seed Industry anticipates a profit of 90 million to 120 million yuan, reversing previous losses [25] - Jifeng Co. expects a profit of 410 million to 495 million yuan, reversing previous losses [26] - Bingchuan Network forecasts a profit of 436 million to 516 million yuan, reversing previous losses [27] - Zhongyou Technology anticipates a profit of 540 million to 640 million yuan, reversing previous losses [28] - Dongfang Biology expects a loss of 523 million yuan [29] - Wantai Biological anticipates a loss of 330 million to 410 million yuan due to market pressures [30] - Anbotong expects a loss of 114 million to 165 million yuan [31] - Shunxin Agriculture forecasts a loss of 116 million to 188 million yuan due to declining sales [32] - Guozhong Water expects a loss of 130 million to 104 million yuan, with potential delisting risks [33] Group 5: Major Contracts - China Communication Signal expects to win 21 major projects worth approximately 5.26 billion yuan [34]

Major Announcements - China Gold announced that its stock trading shows signs of market sentiment overheating, which may lead to a risk of short-term declines after significant price increases. The company's P/E ratio is 55.63, significantly higher than the industry median of 28.60 [1] - Zhaojin Mining stated that the prices of its gold and gold concentrate products are highly influenced by fluctuations in gold prices, which could significantly impact its operating performance if gold prices experience large swings [2] - Silver (Core Stock) Nonferrous reported that the revenue from its gold and silver products constitutes a low proportion of total operating income, with gold product sales accounting for 18.67% and silver product sales for 4.54% of total revenue [3] Company-Specific Risks - Hunan Silver (Core Stock) indicated that it has a relatively low amount of proven metal resources compared to industry peers, which poses a resource reserve risk. The company also faces risks from silver price fluctuations and has a low gross margin of 6.54% compared to mining companies [4] - TianShun Wind Energy decided to implement a long-term shutdown of six wholly-owned subsidiaries due to increasing market competition, aiming to optimize resource allocation and focus on core businesses like offshore wind power [5] - Qidi Environment expects a negative net asset value by the end of 2025, which may lead to a risk warning for its stock trading if the audited net assets are confirmed to be negative [6] Performance Forecasts - BlueFocus anticipates a net profit of 1.8 billion to 2.2 billion yuan for 2025, benefiting from growth in overseas business and improved credit management [12] - Shengyi Technology expects a net profit of 3.25 billion to 3.45 billion yuan for 2025, representing a year-on-year increase of 87% to 98% due to rising sales of copper-clad laminates [13] - Sichuan Gold forecasts a net profit of 420 million to 480 million yuan for 2025, up 69.23% to 93.4% year-on-year, driven by increased sales volume and rising gold prices [14] - Dongfang Communication predicts a net profit of approximately 360 million yuan for 2025, a year-on-year increase of about 138.5%, primarily due to significant investment gains from the disposal of financial assets [15] Other Notable Announcements - Yunnan Copper confirmed that its production and operations are normal, with no undisclosed significant matters, despite its stock experiencing a 20% price fluctuation [9] - Liou Co. reported that its operations are normal, with no undisclosed significant matters, and its stock has also seen a significant price fluctuation [10] - Guosheng Securities expects a net profit of 210 million to 280 million yuan for 2025, reflecting a year-on-year increase of 25.44% to 67.25% due to robust business development [29]

2026.01. 29 本文字数：1466，阅读时长大约3分钟 作者 | 第一财经 林志吟 中国人用疫苗（下称疫苗）出口金额在2024年恢复正增长后，2025年再度出现增长，且增速进一步 提高。 中国医药保健品进出口商会1月29日在公众号上发布的数据显示，2025年，中国疫苗出口金额为 3.24亿美元，同比增长52.63%。 回顾2024年，中国疫苗出口金额为2.12亿美元，同比增长4.92%，彼时是2022年以来首次恢复正 增长，摆脱了过去三年受抗击新冠疫情需求变化而带来的波动影响。 2025年，中国人用疫苗出口到了全球85个市场，前十大市场出口金额占比为70.04%。其中，对巴 基斯坦出口同比增长130.53%，对巴西出口同比增长为119.50%，对缅甸出口增幅甚至高达近30 倍。 长期以来，国内许多疫苗企业聚焦成熟度高且市场风险较小的传统技术路线产品，Me-too（同类仿 创）类管线占比高，且大多集中在宫颈癌疫苗、肺炎球菌疫苗和脑膜炎球菌疫苗等热门疫苗品种，重 磅产品上市时间显著晚于欧美头部企业，进而导致国内疫苗存量市场竞争持续加剧、产品同质化竞争 日益明显。 面对国内疫苗市场竞争愈演愈烈背景下，越来越 ...

2025年，中国疫苗出口到了全球85个市场。 沃森生物（300142.SZ）在1月28日晚间发布的2025年业绩预告中表示，公司国内疫苗产品收入降幅收 窄，趋于平稳，国外疫苗产品收入持续增长，出口疫苗产品收入较上年同期增长约35%。 不过，中国疫苗企业在加大出口的过程中，如何获得更高利润回报，目前仍有待发力。相较2024年疫苗 出口金额靠价格驱动的增长，2025年的出口更多还是靠量取胜。2025年，疫苗出口量增幅高达 130.54%，显示出"量增价跌"的趋势。 长期以来，国内许多疫苗企业聚焦成熟度高且市场风险较小的传统技术路线产品，Me-too（同类仿创） 类管线占比高，且大多集中在宫颈癌疫苗、肺炎球菌疫苗和脑膜炎球菌疫苗等热门疫苗品种，重磅产品 上市时间显著晚于欧美头部企业，进而导致国内疫苗存量市场竞争持续加剧、产品同质化竞争日益明 显。 面对国内疫苗市场竞争愈演愈烈背景下，越来越多的中国疫苗企业加大力度往外走，一些企业借助"一 带一路"沿线国家产业合作机遇，加大海外发展中国家或地区的市场布局力度。在"一带一路"国家中， 不少发展中国家缺乏疫苗生产能力，这给中国疫苗企业出海发展带来机遇。 康泰生物（3006 ...